Letrozole: The treatment profile, the remaining questions

Nevertheless, the results are clinically meaningful. Many women remain at moderate risk of disease recurrence even after a 5-year course of tamoxifen, and letrozole can decrease this risk. In the next few years, multiple trials will provide additional information about aromatase inhibitors as adjuvant therapy. The landscape may well change in the not-so-distant future.

Bottom Line

Physicians should discuss the pros and cons of letrozole therapy with postmenopausal women completing a 5-year course of tamoxifen. However, both doctor and patient must carefully weigh the treatment’s known benefits against potential risks.